Status:
COMPLETED
Treatment-related Benefit and Satisfaction in Fabry Patients. Insight in Patients Expectations and Preferences
Lead Sponsor:
Amicus Therapeutics France SAS
Conditions:
Fabry Disease
Anderson Fabry Disease
Eligibility:
All Genders
16+ years
Brief Summary
In the shared decision-making process, patients should express their expectations and preferences regarding treatment to the physician. A specific questionnaire addressing needs and expectations of Fa...
Detailed Description
Prospective, longitudinal, non-comparative, open-label, multicentre, non interventional cohort study.
Eligibility Criteria
Inclusion
- Patients ≥ 16 years old
- Diagnosed with Fabry disease
- With amenable mutation
- Decision by clinician to start or pursue ongoing ERT or migalastat
- Non-opposition form to participate in the study signed
Exclusion
- \- Concomitant patient participation in an interventional clinical study (Category 1 interventional research or category 2 interventional research according to the Jardé law classification in France)
Key Trial Info
Start Date :
April 4 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 30 2023
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT04043273
Start Date
April 4 2019
End Date
January 30 2023
Last Update
May 23 2024
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU d'Angers
Angers, France, 49000
2
CHU Pellegrin
Bordeaux, France, 33000
3
Hôpital Côte de Nacre
Caen, France, 14033
4
CHU de Dijon
Dijon, France, 21000